专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06538112B2 Hybridomas and monoclonal antibodies for an anticoagulant test 失效
标题翻译：用于抗凝血试验的杂交瘤和单克隆抗体
公开(公告)号：US06538112B2
公开(公告)日：2003-03-25
申请号：US09823444
申请日：2001-03-30
申请人： Bohumil Bednar , Daniel M. Bollag , Robert J. Gould
发明人： Bohumil Bednar , Daniel M. Bollag , Robert J. Gould
IPC分类号： C07K1600
CPC分类号： C07K16/2848 , A61K38/00 , C07K2317/24 , G01N33/68 , G01N33/6893 , G01N2333/70557
摘要： The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combining i) a plasma sample of the patient; ii) detectable monoclonal antibody which recognizes induced binding sites formed on the GP IIb/IIIa receptor following association of a fibrinogen receptor antagonist with the GP IIb/IIIa receptor; and iii) GP IIb/IIIa receptor:GP IIb/III receptor antagonist complex, and determining association of the detectable monoclonal antibody with the complex in the presence of the plasma.
摘要翻译：本发明是一种用于诊断通过给予GP IIb / IIIa受体拮抗剂诱导的血小板减少症的患者的方法，所述方法包括组合患者的血浆样品; ii）识别诱导结合位点上形成的诱导结合位点的可检测单克隆抗体 GP IIb / IIIa受体与纤维蛋白原受体拮抗剂与GP IIb / IIIa受体结合后，和ii）GP IIb / IIIa受体：GP IIb / III受体拮抗剂复合物，以及在血浆存在下确定可检测单克隆抗体与复合物的缔合。

2. 发明授权

US06210904B1 Anticoagulant test 失效
标题翻译：抗凝血试验
公开(公告)号：US06210904B1
公开(公告)日：2001-04-03
申请号：US09170858
申请日：1998-10-13
申请人： Bohumil Bednar , Daniel M. Bollag , Robert J. Gould
发明人： Bohumil Bednar , Daniel M. Bollag , Robert J. Gould
IPC分类号： G01N3353
CPC分类号： C07K16/2848 , A61K38/00 , C07K2317/24 , G01N33/68 , G01N33/6893 , G01N2333/70557
摘要： The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combining i) a plasma sample of the patient; ii) detectable monoclonal antibody which recognizes induced binding sites formed on the GP IIb/IIIa receptor following association of a fibrinogen receptor antagonist with the GP IIb/IIIa receptor; and iii) GP IIb/IIIa receptor:GP IIb/III receptor antagonist complex, and determining association of the detectable monoclonal antibody with the complex in the presence of the plasma.
摘要翻译：本发明是一种用于诊断通过给予GP IIb / IIIa受体拮抗剂诱导的血小板减少症的患者的方法，所述方法包括组合患者的血浆样品; ii）识别诱导结合位点上形成的诱导结合位点的可检测单克隆抗体 GP IIb / IIIa受体与纤维蛋白原受体拮抗剂与GP IIb / IIIa受体结合后，和ii）GP IIb / IIIa受体：GP IIb / III受体拮抗剂复合物，以及在血浆存在下确定可检测单克隆抗体与复合物的缔合。

3. 发明授权

US5646000A Compounds and methods for identifying activated platelets 失效
标题翻译：用于鉴定活化血小板的化合物和方法
公开(公告)号：US5646000A
公开(公告)日：1997-07-08
申请号：US315034
申请日：1994-09-29
申请人： Bohumil Bednar , Melissa Egbertson , Robert J. Gould , George D. Hartman , Jules A. Shafer
发明人： Bohumil Bednar , Melissa Egbertson , Robert J. Gould , George D. Hartman , Jules A. Shafer
IPC分类号： C07D401/06 , C07D405/14 , C07D491/22 , C07D495/04 , G01N33/569 , G01N33/80 , G01N33/86 , G01N33/567 , C07D401/14
CPC分类号： C07D401/06 , C07D405/14 , C07D495/04 , G01N33/56966 , G01N33/80 , G01N33/86 , G01N2500/00 , Y10S436/80 , Y10S436/811
摘要： The invention is directed to a series of novel compounds, and their pharmaceutically acceptable salts, of the formula ##STR1## wherein R is C.sub.0-6 alkyl substituted with R.sup.5 or a mono or polycyclic aromatic or heteroaromatic system comprised of 5 or 6-membered aromatic or heteroaromatic rings that are either unsubstituted or substituted with one or more of R.sup.1 and R.sup.2 ; R.sup.1 and R.sup.2 are independently C.sub.1-6 alkyl, carboxyl, hydroxyl, azido, nitro, amino, C.sub.1-6 alkylamino, C.sub.1-6 dialkylamino, arylamino, aryl C.sub.1-6 alkylamino, hydroxysulfonyl or arylazo; aryl is a phenyl or naphthyl ring which is unsubstituted or substituted with one or more of R.sup.3 and R.sup.4 ; R.sup.3 and R.sup.4 are independently C.sub.1-6 alkyl, azido, nitro, amino, C.sub.1-6 dialkylamino or hydroxysulfonyl; R.sup.5 is ##STR2## provided that when R is an unsubstituted monocyclic ring, the monocyclic ring is not phenyl or pyridyl. Such compounds are useful as fluorescent probes for identifying antiplatelet agents which selectively bind to activated platelets.
摘要翻译：本发明涉及一系列新颖的化合物及其药学上可接受的盐，其中R是被R 5取代的C 1-6烷基或由5或6元芳族的单或多环芳族或杂芳族体系或未被取代或被一个或多个R 1和R 2取代的杂芳环; R 1和R 2独立地是C 1-6烷基，羧基，羟基，叠氮基，硝基，氨基，C 1-6烷基氨基，C 1-6二烷基氨基，芳基氨基，芳基C 1-6烷基氨基，羟基磺酰基或芳基偶氮; 芳基是未被取代或被一个或多个R 3和R 4取代的苯基或萘基环; R 3和R 4独立地为C 1-6烷基，叠氮基，硝基，氨基，C 1-6二烷基氨基或羟基磺酰基; R5是或，条件是当R是未取代的单环时，单环不是苯基或吡啶基。这样的化合物可用作识别选择性结合活化血小板的抗血小板剂的荧光探针。

4. 发明授权

US6063584A Anticoagulant test 失效
标题翻译：抗凝血试验
公开(公告)号：US6063584A
公开(公告)日：2000-05-16
申请号：US975312
申请日：1997-11-21
申请人： Bohumil Bednar , Robert J. Gould
发明人： Bohumil Bednar , Robert J. Gould
IPC分类号： G01N33/566 , G01N33/86
CPC分类号： G01N33/566 , G01N33/86
摘要： The present invention is a method for identifying a patient at risk to developing fibrinogen receptor antagonist-induced thrombocytopenia which comprises incubating patient plasma with a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist complex to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex, incubating the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex with a secondary anti-human detectable antibody to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex, and detecting the presence of the secondary anti-human detectable antibody in the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex.
摘要翻译：本发明是用于鉴定处于发展纤维蛋白原受体拮抗剂诱发的血小板减少症的风险的患者的方法，其包括将患者血浆与GPIIb / IIIa受体：GPIIb / IIIa受体拮抗剂复合物孵育以形成GPIIb / IIIa受体：GPIIb / IIIa受体拮抗剂：血浆抗体复合物，培养GPIIb / IIIa受体：GPIIb / IIIa受体拮抗剂：血浆抗体复合物与第二抗人可检测抗体形成GPIIb / IIIa受体：GPIIb / IIIa受体拮抗剂：血浆抗体：人类可检测的抗体复合物，并检测GPIIb / IIIa受体中二级抗人可检测抗体的存在：GPIIb / IIIa受体拮抗剂：血浆抗体：第二抗人可检测抗体复合物。

5. 发明授权

US4269962A Electron resist 失效
标题翻译：电子抗蚀剂
公开(公告)号：US4269962A
公开(公告)日：1981-05-26
申请号：US955457
申请日：1978-10-27
申请人： Jaroslav Kalal , Bohumil Bednar , Jaromir Zachoval , Jiri Petr , Zdenek Pelcbauer , Frantisek Svec
发明人： Jaroslav Kalal , Bohumil Bednar , Jaromir Zachoval , Jiri Petr , Zdenek Pelcbauer , Frantisek Svec
IPC分类号： C08F20/00 , C08F20/32 , C08F236/00 , C08F236/04 , G03F7/038 , H01L21/027 , B41N1/08 , C08F220/20 , C08F236/14 , G03F7/10
CPC分类号： G03F7/0388
摘要： The invention relates to a negative electron resist for application in electron lithography. It consists of an organic copolymer formed by copolymerization of butadiene or isoprene with glycidyl acrylate or glycidyl methacrylate. The resist exhibits the high sensitivity to irradiation by electrons and, at the same time, a good adhesion to the base and a resistance towards common etching agents. The copolymer is advantageously prepared by radical polymerization and a high purity of the product does not require further purification. The electron resist manufactured in this way has the long-term workability.
摘要翻译：本发明涉及用于电子光刻的负电子抗蚀剂。它由通过丁二烯或异戊二烯与丙烯酸缩水甘油酯或甲基丙烯酸缩水甘油酯共聚形成的有机共聚物组成。抗蚀剂表现出对电子照射的高灵敏度，同时对基底具有良好的粘附性和对常见蚀刻剂的抵抗力。共聚物有利地通过自由基聚合制备，并且高纯度的产物不需要进一步纯化。以这种方式制造的电子抗蚀剂具有长期的可加工性。

6. 发明授权

US08685370B2 Integrin targeting agents and in-vivo and in-vitro imaging methods using the same 有权
标题翻译：整合素靶向剂和使用其的体内和体外成像方法
公开(公告)号：US08685370B2
公开(公告)日：2014-04-01
申请号：US12922594
申请日：2009-03-13
申请人： Milind Rajopadhye , Guojie Ho , Bohumil Bednar , Le T. Duong , Paul J. Coleman
发明人： Milind Rajopadhye , Guojie Ho , Bohumil Bednar , Le T. Duong , Paul J. Coleman
IPC分类号： A61K49/00
CPC分类号： A61K49/04 , A61K47/65 , A61K49/0002 , A61K49/0032 , A61K49/0052 , A61K49/0056 , A61K49/0065 , A61K49/085 , A61K49/10 , A61K49/1839 , A61K51/0455 , A61K51/0459 , A61K51/0497 , B82Y5/00 , C09B23/0008 , C09B23/083 , C09B23/086 , G01N33/574
摘要： The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
摘要翻译：本发明提供靶向整联蛋白的药物家族，其可以用作成像剂和/或治疗剂。这些药剂可用于影像受试者的血管生成，炎症或其他生理过程。

7. 发明申请

US20110165075A1 INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME 有权
标题翻译： INTEGRIN定位试剂和使用该方法的体内和体外成像方法
公开(公告)号：US20110165075A1
公开(公告)日：2011-07-07
申请号：US12922594
申请日：2009-03-13
申请人： Milind Rajopadhye , Guojie Ho , Bohumil Bednar , Le T. Duong , Paul J. Coleman
发明人： Milind Rajopadhye , Guojie Ho , Bohumil Bednar , Le T. Duong , Paul J. Coleman
IPC分类号： A61K51/00 , C07D471/04 , C07F15/02 , C07F5/00 , C07K7/06 , A61K49/00 , A61K49/04 , G01N33/53
CPC分类号： A61K49/04 , A61K47/65 , A61K49/0002 , A61K49/0032 , A61K49/0052 , A61K49/0056 , A61K49/0065 , A61K49/085 , A61K49/10 , A61K49/1839 , A61K51/0455 , A61K51/0459 , A61K51/0497 , B82Y5/00 , C09B23/0008 , C09B23/083 , C09B23/086 , G01N33/574
摘要： The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
摘要翻译：本发明提供靶向整联蛋白的药物家族，其可以用作成像剂和/或治疗剂。这些药剂可用于影像受试者的血管生成，炎症或其他生理过程。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式